NASDAQ:CGEM

Cullinan Oncology Competitors

$32.30

-1.88 (-5.50 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$31.63

Now: $32.30▼

$34.80

50-Day Range

$34.18

MA: $43.17▼

$53.42

52-Week Range

$27.01

Now: $32.30▼

$59.85

Volume74,100 shs

Average Volume293,677 shs

Market Capitalization$1.41 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Cullinan Oncology (NASDAQ:CGEM) Vs. ABCM, SEER, NUVB, IBRX, BCAB, and IMCR

Should you be buying CGEM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cullinan Oncology, including Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), and Immunocore (IMCR).

Cullinan Oncology vs. Abcam Stock

Abcam (NASDAQ:ABCM) and Cullinan Oncology (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abcam and Cullinan Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0	4	3	0	2.43
Cullinan Oncology	0	1	3	0	2.75

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 10.61%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Abcam.

Valuation and Earnings

This table compares Abcam and Cullinan Oncology's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	N/A	N/A	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Abcam and Cullinan Oncology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A

Summary

Cullinan Oncology beats Abcam on 2 of the 2 factors compared between the two stocks.

Cullinan Oncology vs. Seer Stock

Seer (NASDAQ:SEER) and Cullinan Oncology (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Cullinan Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0	2	2	0	2.50
Cullinan Oncology	0	1	3	0	2.75

Seer presently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Seer.

Valuation and Earnings

This table compares Seer and Cullinan Oncology's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	N/A	N/A	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Seer and Cullinan Oncology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A

Summary

Cullinan Oncology beats Seer on 3 of the 3 factors compared between the two stocks.

Cullinan Oncology vs. Nuvation Bio Stock

Cullinan Oncology (NASDAQ:CGEM) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Cullinan Oncology and Nuvation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Oncology	0	1	3	0	2.75
Nuvation Bio	0	0	6	0	3.00

Cullinan Oncology presently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Cullinan Oncology.

Valuation & Earnings

This table compares Cullinan Oncology and Nuvation Bio's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Cullinan Oncology and Nuvation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Oncology	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A

Summary

Nuvation Bio beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Cullinan Oncology vs. ImmunityBio Stock

Cullinan Oncology (NASDAQ:CGEM) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and ImmunityBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Oncology	0	1	3	0	2.75
ImmunityBio	0	0	1	0	3.00

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 48.19%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than ImmunityBio.

Valuation and Earnings

This table compares Cullinan Oncology and ImmunityBio's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Cullinan Oncology and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Oncology	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Summary

Cullinan Oncology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology vs. BioAtla Stock

Cullinan Oncology (NASDAQ:CGEM) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and BioAtla, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Oncology	0	1	3	0	2.75
BioAtla	0	0	4	0	3.00

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. BioAtla has a consensus target price of $58.00, suggesting a potential upside of 22.49%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than BioAtla.

Valuation and Earnings

This table compares Cullinan Oncology and BioAtla's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A
BioAtla	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Cullinan Oncology and BioAtla's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Oncology	N/A	N/A	N/A
BioAtla	N/A	N/A	N/A

Summary

BioAtla beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology vs. Immunocore Stock

Cullinan Oncology (NASDAQ:CGEM) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Cullinan Oncology and Immunocore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Oncology	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A

Valuation and Earnings

This table compares Cullinan Oncology and Immunocore's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and Immunocore, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Oncology	0	1	3	0	2.75
Immunocore	0	1	2	0	2.67

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Immunocore has a consensus target price of $54.3333, suggesting a potential upside of 53.18%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Cullinan Oncology.

Summary

Cullinan Oncology beats Immunocore on 2 of the 3 factors compared between the two stocks.